Takeaway
Early-onset progressive dysexecutive syndrome (PDS) with biomarkers for Alzheimer’s disease (AD) should be explored as an atypical clinical phenotype that can be due to AD.
Why this matters
Atypical clinical phenotypes of AD without specific diagnostic criteria are often encountered, leading to delayed- or misdiagnosis.
Identifying atypical phenotypes might facilitate earlier and accurate diagnosis and treatment, with direct implications for patient outcomes.